Company / Total Debt
Halozyme Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$2.1B
FY2025
5-year range
$787.3M / $2.1B
FY2021-FY2025
Trend
+42.3%
vs FY2024
Sector context
#20 of 83
Health Care
What the data says
Halozyme's total debt of $2.1B is higher than 76% of companies in the Health Care sector (FY2025). Total Debt has fluctuated over the past 10 years, ranging from $0 in FY2020 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 3-year CAGR of +12.5%. Top quartile in the Health Care sector.
Increased from $1.5B to $2.1B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +12.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 83This company $2.1B Sector average $6.2B
▼
-65.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +12.5%, indicating consistent growth.
- In FY2025, total debt increased 42.3% year-over-year.
- Ranks #20 out of 83 companies in the Health Care sector.
- Lowest total debt in the period was in FY2020.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +42.3% |
| FY2024 | $1.5B | +0.4% |
| FY2023 | $1.5B | -0.5% |
| FY2022 | $1.5B | +91.3% |
| FY2021 | $787.3M | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $383.0M | +998.4% |
| FY2018 | $34.9M | -72.1% |
| FY2017 | $125.1M | -37.2% |
| FY2016 | $199.2M | +612.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026